JP2009502937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502937A5 JP2009502937A5 JP2008524094A JP2008524094A JP2009502937A5 JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5 JP 2008524094 A JP2008524094 A JP 2008524094A JP 2008524094 A JP2008524094 A JP 2008524094A JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- kinase
- abl kinase
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091000080 Phosphotransferase Proteins 0.000 claims 10
- 102000020233 phosphotransferase Human genes 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70277105P | 2005-07-26 | 2005-07-26 | |
| US78516106P | 2006-03-23 | 2006-03-23 | |
| US83025706P | 2006-07-12 | 2006-07-12 | |
| PCT/US2006/028984 WO2007014250A2 (en) | 2005-07-26 | 2006-07-26 | Abl kinase inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012122081A Division JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ａｂｌキナーゼ阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502937A JP2009502937A (ja) | 2009-01-29 |
| JP2009502937A5 true JP2009502937A5 (enExample) | 2009-09-10 |
Family
ID=37683933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524094A Pending JP2009502937A (ja) | 2005-07-26 | 2006-07-26 | Ａｂｌキナーゼ阻害 |
| JP2012122081A Pending JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ａｂｌキナーゼ阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012122081A Pending JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ａｂｌキナーゼ阻害 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090298844A1 (enExample) |
| EP (1) | EP1906967A4 (enExample) |
| JP (2) | JP2009502937A (enExample) |
| AU (1) | AU2006272609A1 (enExample) |
| CA (1) | CA2616517A1 (enExample) |
| WO (1) | WO2007014250A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197893A1 (en) * | 2005-12-01 | 2009-08-06 | Bristol-Myers Squibb Company | Methods of Identifying and Treating Individuals Exhibiting Complex Karyotypes |
| WO2008013807A2 (en) * | 2006-07-26 | 2008-01-31 | Merck & Co., Inc. | A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
| RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| KR102350704B1 (ko) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| CN111793068A (zh) | 2013-03-15 | 2020-10-20 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| SI3424920T1 (sl) | 2013-10-17 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk |
| KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2017335E (pt) * | 2001-10-05 | 2011-03-02 | Novartis Ag | Domínios da cinase abl mutados |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| SG155222A1 (en) * | 2004-08-13 | 2009-09-30 | Genentech Inc | Thiazole based inhibitors of atp-utilizing enzymes |
-
2006
- 2006-07-26 EP EP06800350A patent/EP1906967A4/en not_active Withdrawn
- 2006-07-26 WO PCT/US2006/028984 patent/WO2007014250A2/en not_active Ceased
- 2006-07-26 JP JP2008524094A patent/JP2009502937A/ja active Pending
- 2006-07-26 AU AU2006272609A patent/AU2006272609A1/en not_active Abandoned
- 2006-07-26 US US11/989,300 patent/US20090298844A1/en not_active Abandoned
- 2006-07-26 CA CA002616517A patent/CA2616517A1/en not_active Abandoned
-
2012
- 2012-05-29 JP JP2012122081A patent/JP2012158616A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103402514B (zh) | 用于治疗运动障碍的血清素受体激动剂组合物 | |
| JP2005506370A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| AU2013245027B2 (en) | Use of CCR3-inhibitors | |
| NO20081843L (no) | Farmasoytisk sammensetning for forbedret kognitiv funksjon | |
| JP2010529118A5 (enExample) | ||
| EA201692214A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| JP2009541443A5 (enExample) | ||
| JP2008502696A5 (enExample) | ||
| JP2009502937A5 (enExample) | ||
| JP2018090566A5 (enExample) | ||
| JP2009062388A5 (enExample) | ||
| JP2009541409A5 (enExample) | ||
| JP2005500370A5 (enExample) | ||
| WO2008137809A3 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof | |
| JP2007501270A5 (enExample) | ||
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| TNSN08506A1 (en) | Substituted carboxamides | |
| EA200800783A1 (ru) | Композиция тразодона для введения один раз в день | |
| JP2008534503A5 (enExample) | ||
| WO2010004221A3 (fr) | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson | |
| NO20065152L (no) | Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav | |
| JP2008513426A5 (enExample) |